Yuanyuan Xie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yuanyuan Xie has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Cristina R. Antonescu
Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY
10 shared publications Devan Murphy
10 shared publications- Dong Gao
Department of Environmental Health Sciences, Yale School of Public Health, New Haven, USA
10 shared publications Ferdinando Rossi
10 shared publications- Ingo K. Mellinghoff
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, USA
10 shared publications Inna Sirota
10 shared publications
Latest Publications
- 29 October 2026
- Published by Taylor & Francis in Cell Cycle
- Vol. 25 (1) , 1-19
Integrative whole-exome sequencing and functional validation identify drivers of lung cancer metastasis seeding and colonization in the brain
- 29 October 2026
- Published by Taylor & Francis in Cell Cycle
- Vol. 25 (1) , 1-19
Integrative whole-exome sequencing and functional validation identify drivers of lung cancer metastasis seeding and colonization in the brain
- Open Access
- 1 January 2024
- Published by Wiley in Analytical Cellular Pathology
- Vol. 2024 (1)
Construction and Validation of an Oxidative Phosphorylation Signature in High‐Grade Glioma and Potential Inhibitors Screening
Glioma is a devastating type of brain tumor with high morbidity and mortality rates. Despite current treatment options, the prognosis for glioma patients remains poor. Metabolic reprograming has emerged as a crucial aspect of tumorigenesis, and the oxidative phosphorylation pathway has received increasing attention as a promising target for cancer treatment. In this study, we conducted a comprehensive analysis of transcriptome data to identify differentially expressed genes related to oxidative phosphorylation in glioma. Based on these findings, we developed the first oxidative phosphorylation‐based prognostic and diagnostic signatures and investigated the methylation level of oxidative phosphorylation‐related genes, constructed miRNA–mRNA regulatory networks, and screened potential oxidative phosphorylation pathway inhibitors. Moreover, we analyzed the immune cell infiltration pattern based on oxidative phosphorylation‐related genes’ expression and found that the high‐oxidative phosphorylation group had more inhibitory immune cell infiltration. Overall, this study provides novel insights into the possible molecular mechanisms of oxidative phosphorylation in glioma progression and identifies potential targets for future glioma therapy.
- 1 January 2024
- Published by Wiley in Analytical Cellular Pathology
- Vol. 2024 (1)
Open AccessConstruction and Validation of an Oxidative Phosphorylation Signature in High‐Grade Glioma and Potential Inhibitors Screening
Glioma is a devastating type of brain tumor with high morbidity and mortality rates. Despite current treatment options, the prognosis for glioma patients remains poor. Metabolic reprograming has emerged as a crucial aspect of tumorigenesis, and the oxidative phosphorylation pathway has received increasing attention as a promising target for cancer treatment. In this study, we conducted a comprehensive analysis of transcriptome data to identify differentially expressed genes related to oxidative phosphorylation in glioma. Based on these findings, we developed the first oxidative phosphorylation‐based prognostic and diagnostic signatures and investigated the methylation level of oxidative phosphorylation‐related genes, constructed miRNA–mRNA regulatory networks, and screened potential oxidative phosphorylation pathway inhibitors. Moreover, we analyzed the immune cell infiltration pattern based on oxidative phosphorylation‐related genes’ expression and found that the high‐oxidative phosphorylation group had more inhibitory immune cell infiltration. Overall, this study provides novel insights into the possible molecular mechanisms of oxidative phosphorylation in glioma progression and identifies potential targets for future glioma therapy.